Related Experiment Video

Updated: Jun 5, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]

Krisztina Biró1, Zsófia Küronya

  • 1Országos Onkológiai Intézet 1122 Budapest Ráth György u. 7-9. birok@oncol.hu

Magyar Onkologia
|December 18, 2010
PubMed

Insights

New targeted therapies, including tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, are now standard for advanced clear-cell renal cell carcinoma (RCC). Treatment choice depends on patient risk and prior therapies, guided by international guidelines.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Clear-cell renal cell carcinoma (ccRCC) biology has advanced, leading to targeted therapies.
  • Tyrosine kinase inhibitors (TKIs) and mTOR inhibitors are now standard for advanced ccRCC.

Purpose of the Study:

  • To review recent advancements in clear-cell RCC treatment.
  • To focus on international guidelines for managing metastatic ccRCC.

Main Methods:

  • Review of randomized studies and international guidelines.
  • Analysis of evidence for first-line and subsequent therapies.

Main Results:

  • First-line therapy for good/intermediate-risk mRCC: sunitinib, pazopanib, or bevacizumab plus interferon.
  • Other options include sorafenib, high-dose interleukin-2, and temsirolimus for poor prognosis.
  • For cytokine-refractory or TKI-progressed patients, sorafenib or everolimus are recommended.

Conclusions:

  • Treatment selection for metastatic ccRCC should be evidence-based, guided by risk stratification and prior treatment response.
  • Targeted agents represent a significant advancement in ccRCC management.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...